Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT and Dual-burst Xanomeline/Trospium PK/Safety in Adolescents
NCT06853171Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trospium in schizophrenia, schizoaffective disorder, bipolar I disorder and 4 more (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with Serious Adverse Events (SAEs) and 1 more. Started Apr 2025; status: completed.
02
Drugs
trospium
03
Conditions
schizophreniaschizoaffective disorderbipolar I disorderBipolar II disorder (BP-II)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06853171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853171.